热带病与寄生虫学 ›› 2020, Vol. 18 ›› Issue (4): 231-233.

• 防治研究 • 上一篇    下一篇

湖南省腹水型晚期血吸虫病合并乙型肝炎患者抗病毒治疗现状分析

王洪波,荆群山,郑娜,陶江,谢韵,彭妮娜
  

  1. 湖南省血吸虫病防治所,国家血吸虫病临床重点专科,WHO 湖区血吸虫病防治合作中心,血吸虫病免疫与传播控制湖南省重点实验室,岳阳 414000
  • 出版日期:2020-11-27 发布日期:2020-11-27
  • 作者简介:王洪波,男,本科,副主任医师,研究方向:血吸虫病基础与临床。 E-mail:baimoshuiwhb@126.com
  • 基金资助:
    国家血吸虫病临床重点专科建设项目(卫办医政函〔2012〕649)

Analysis on the antiviral treatment of advanced schistosomiasis with ascites and hepatitis B,Hunan Province 

WANG Hong-bo, JING Qun-shan, ZHENG Na, TAO Jiang, XIE Yun, PENG Ni-na    

  1. Hunan Provicial Institute of Schistosomiasis Control, National Key Clinical Specialty, WHO Collaborating Center on Schistosomiasis
    Control in Lake Regions
    , Hunan Key Laboratory of Immunology and Transmission Control of Schistosomiasis, Yueyang 41400, China
  • Online:2020-11-27 Published:2020-11-27

摘要: 目的 了解湖南省腹水型晚期血吸虫病合并乙型肝炎患者的抗病毒治疗现状,进一步规范治疗方法  对湖南省血吸虫病防治所湘岳医院国家血吸虫病临床重点专科 2018 年全年收治的 117 例腹水型晚期血吸虫病合并乙型肝炎患者的临床资料进行回顾性分析,并进行随访观察结果 117 例腹水型晚期血吸虫病合并乙型肝炎患者中,男性 85 ,女性 32 ;年龄 33~ 86 ,平均年龄(53. 99±11. 46)进行抗病毒治疗人数 71 ,占比 60. 7%;48 例选用阿德福韦酯,44 例获得病毒学应答,2 例出现耐药,另有 2 例因上消化道出血死亡;23 例使用恩替卡韦,均获得病毒学应答46 例患者未进行抗病毒治疗,主要由于经济压力以及治疗时间长结论 腹水型晚期血吸虫病合并乙型肝炎的比例较高,应进一步规范化抗乙肝病毒治疗

关键词: 晚期血吸虫病, 腹水, 乙型肝炎, 抗病毒治疗

Abstract: Objective To understand the current situation of antiviral treatment of advanced schistosomiasis patients with ascites and hepatitis B for further standardizing the clinical treatment protocol. Methods The clinical data were retrospectively analyzed in 117 patients of advanced schistosomiasis with ascites concomitant with hepatitis B, admitted to and treated in 2018 in the National Key Clinical Specialty of Schistosomiasis of Xiangyue Hospital affiliated to Hunan Provincial Institute of Schistosomiasis Control. All patients were followed up. Results Of the 117 cases of advanced schistosomiasis with hepatitis B, 85 were males and 32 females. The patients aged from 33 to 86 years old, with an average of (53. 99 ± 11. 46) years. Seventy-one (60. 7% ) received antiviral therapy, in whom 48 were treated with adefovir dipivoxil and 44 with virological response. Drug resistance occurred in 2 patients, and death occurred in another 2 from upper gastrointestinal hemorrhage. Virological response was achieved in the 23 patients treated by entecavir. Forty-six patients did not receive antiviral treatment due to economic reasons and failure of compliance with long-term treatment course. Conclusion The proportion of advanced schistosomiasis with ascites and hepatitis B is high, and standardized anti-hepatitis B treatment should be strengthened.

Key words: Advanced schistosomiasis, Ascites, Hepatitis B, Antiviral therapy

中图分类号: